Dacomitinib
Names | |
---|---|
Pronunciation | dak" oh mi' ti nib |
Trade names | Vizimpro |
Other names | PF-00299804 |
| |
Clinical data | |
Drug class | EGFR inhibitor[1] |
Main uses | Non-small-cell lung carcinoma (NSCLC)[2] |
Routes of use | By mouth |
Typical dose | 45 mg OD[3] |
External links | |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618055 |
Legal | |
License data |
|
Legal status |
|
Pharmacokinetics | |
Bioavailability | 80% |
Protein binding | 98% |
Metabolism | CYP2D6, CYP3A4 |
Metabolites | O-desmethyl-dacomitinib |
Elimination half-life | 70 hrs |
Excretion | 79% faeces, 3% urine |
Chemical and physical data | |
Formula | C24H25ClFN5O2 |
Molar mass | 469.95 g·mol−1 |
3D model (JSmol) | |
| |
|
Dacomitinib, sold under the brand name Vizimpro, is a medication used to treat non-small-cell lung carcinoma (NSCLC).[2] Specifically it is used for cases with certain epidermal growth factor receptor (EGFR) mutations.[2] It is taken by mouth.[2]
Common side effects include diarrhea, rash, mouth inflammation, conjunctivitis, itching, liver problems, and nausea.[3] Other side effects may include interstitial lung disease.[3] Use in pregnancy may harm the baby.[2] It is a tyrosine kinase inhibitor of EGFR.[1]
Dacomitinib was approved for medical use in the United States in 2018 and Europe in 2019.[2][3] In the United States it costs about 14,300 USD per month as of 2021.[4] This amount in the United Kingdom costs the NHS about £2,700.[5]
Medical uses
Dosage
The typical dose is 45 mg per day.[3]
Research
Dacomitinib has advanced to several Phase III clinical trials.[when?] The January 2014 results of the first trials were disappointing, with a failure to meet the study goals.[6][7][8] Additional Phase III trials are ongoing[when?].[6]
References
- ↑ 1.0 1.1 "Dacomitinib". NCI Drug Dictionary. National Cancer Institute, U.S. Department of Health and Human Services. Archived from the original on 28 April 2015. Retrieved 31 May 2021.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 "Dacomitinib Monograph for Professionals". Drugs.com. Archived from the original on 1 January 2022. Retrieved 17 December 2021.
- ↑ 3.0 3.1 3.2 3.3 3.4 "Vizimpro EPAR". European Medicines Agency (EMA). 5 June 2019. Archived from the original on 13 December 2019. Retrieved 13 December 2019.
- ↑ "Vizimpro Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 28 May 2019. Retrieved 17 December 2021.
- ↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1021. ISBN 978-0857114105.
- ↑ 6.0 6.1 Chustecka Z (27 January 2014). "Dacomitinib Fails in Pretreated Non-small Cell Lung Cancer". Medscape. Archived from the original on 13 June 2017. Retrieved 31 May 2021.
- ↑ Taylor P (28 January 2014). "Blow to Pfizer as dacomitinib fails in lung cancer trials". pmlive.com. Archived from the original on 5 March 2019. Retrieved 31 May 2021.
- ↑ "Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer". Pfizer Press Release. 27 January 2014. Archived from the original on 11 June 2019. Retrieved 31 May 2021.
External links
External sites: | |
---|---|
Identifiers: |
|
- Pages using duplicate arguments in template calls
- Use dmy dates from December 2019
- Articles with invalid date parameter in template
- Drugs with non-standard legal status
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Chemicals using indexlabels
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- All articles with vague or ambiguous time
- Vague or ambiguous time from December 2019
- Anilines
- Antineoplastic drugs
- Piperidines
- Pfizer brands
- Quinazolines
- Orphan drugs
- RTT
- All stub articles
- Antineoplastic and immunomodulating drug stubs